Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 3 4Phase 2 4Phase 2/3 1Phase 1/2 1

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 2Genitourinary 2Tumor-Agnostic 1Thoracic 1Head & Neck 1

Conditions

Carcinoma, Renal Cell 2Prostatic Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × sitravatinib × Clear all
NCT03666143 2024-11-04

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

BeiGene

Phase 1 Completed
216 enrolled 20 charts
Other solid neoplasm

Advanced Solid Tumors

NCT04472650 2024-10-26

Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults

BeiGene

Phase 1 Completed
26 enrolled 14 charts
Tumor-Agnostic

Neoplasms

NCT04518046 2024-06-05

Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Mirati Therapeutics Inc.

Phase 1 Completed
22 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04887194 2024-05-08

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Mirati Therapeutics Inc.

Phase 1 Completed
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT02219711 2023-03-06

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

Mirati Therapeutics Inc.

Phase 1 Completed
193 enrolled
GenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡